home / stock / shpmf / shpmf news
2023-09-17 08:35:00 ET Summary Shanghai Hasten Biopharma has entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Insilico Medicine has out-licensed global rights to a small molecule inhibitor to Exelixis for BRCA-mutated tumors. ...
Summary Sichuan Kelun-Biotech will partner seven preclinical antibody-drug conjugate assets with Merck in a deal that pays Kelun-Biotech $175 million upfront and up to $9.3 billion in milestones - the third ADC deal between the two companies this year. LianBio announced that Pfizer will...
Shanghai Fosun Pharma announced a $628 million deal to acquire a 73% stake in vaccine company Chengdu Antejin Biotech. Shanghai Pharma subsidiary SPH SINE acquired greater China rights for two microbiome therapies from Korea's KoBioLabs in a $110 million deal. Suzhou Innovent and ...
LianBio Launches to Bring US Assets to China; Announces $719 Million of In-Licensings Perceptive Advisors is launching LianBio to bring US biopharma assets to China. A successful fund operator, Perceptive has made investments in 150 public and 80 private biopharmas and has strong connectio...
Deals and Financings China Biologic Products (CBPO), a blood products company, received a $4.6 billion takeover offer from a group of six investment firms (see story ). The proposal was priced at $120 per share, a 16% premium to the previous close. CBPO operates plasma-gathering facilities ...